FDAnews Drug Daily Bulletin

CERAGENIX RECEIVES 510K CLEARANCE OF EPICERAM

April 13, 2006
A A

Ceragenix Pharmaceuticals, Inc., a biopharmaceutical company focused on infectious disease and dermatology, today announced it has received 510K clearance from the U.S. Food and Drug Administration ("FDA") for its EpiCeram Skin Barrier Emulsion to improve dry skin conditions and to relieve and manage the burning and itching associated with various dermatoses including atopic dermatitis, irritant contact dermatitis, radiation dermatitis, and other dry skin conditions by maintaining a moist wound and skin environment.
Genetic Engineering News